A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile

被引:50
|
作者
Hanna, Czajka [1 ]
Volker, Schuster [2 ]
Fred, Zepp [3 ]
Susanna, Esposito [4 ]
Martine, Douha [4 ]
Paul, Willems [5 ]
机构
[1] Szpital Sw Ludwika, Vaccinat Outpatient Clin, PL-31503 Krakow, Poland
[2] Univ Leipzig, Hosp Children & Adolescents, D-04103 Leipzig, Germany
[3] Johannes Gutenberg Univ Mainz, Univ Hosp, Dept Pediat, D-55131 Mainz, Germany
[4] Univ Milan, Inst Pediat, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Milan, Italy
[5] GlaxoSmithKline Biol, Rixensart, Belgium
关键词
Combined MMRV vaccine; Immunogenicity; Reactogenicity; ASEPTIC-MENINGITIS; HEALTHY-CHILDREN; REACTOGENICITY; PREVENTION; DECLINE; EUROPE; MMR;
D O I
10.1016/j.vaccine.2009.07.076
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Priorix-Tetra (TM) (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix (TM)) and varicella (Varilrix (TM)) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines. offering a convenient way to introduce varicella vaccination into routine vaccination programmes. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6504 / 6511
页数:8
相关论文
共 50 条
  • [1] A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile (vol 27, pg 6504, 2009)
    Czajka, Hanna
    Schuster, Volker
    Zepp, Fred
    Esposito, Susanna
    Douha, Martine
    Willems, Paul
    [J]. VACCINE, 2012, 30 (52) : 7667 - 7667
  • [2] A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra ⟨trade⟩): Immunogenicity and safety profile (vol 27, pg 6504, 2009)
    Czajka, Hanna
    Schuster, Volker
    Zepp, Fred
    Esposito, Susanna
    Douha, Martine
    Willems, Paul
    [J]. VACCINE, 2010, 28 (52) : 8352 - 8352
  • [3] Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra™)
    Dhillon S.
    Curran M.P.
    [J]. Pediatric Drugs, 2008, 10 (5) : 337 - 347
  • [4] Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad®)
    Kuter, Barbara J.
    Brown, Michelle L. Hoffman
    Hartzel, Jonathan
    Williams, Wendy R.
    Eves, Karen A.
    Black, Steve
    Shinefield, Henry
    Reisinger, Keith S.
    Marchant, Colin D.
    Sullivan, Bradley J.
    Thear, Marci
    Klopfer, Stephanie
    Xu, Jin
    Gress, Jacqueline O.
    Schoedel, Florian
    [J]. HUMAN VACCINES, 2006, 2 (05): : 205 - 214
  • [5] Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV—Priorix-Tetra™) Compared to Separate MMR + V Vaccination
    Vincent Bauchau
    Lionel Van Holle
    Carine Cohen
    [J]. Drug Safety, 2015, 38 : 1095 - 1102
  • [6] COMBINED VACCINE AGAINST MEASLES, MUMPS, RUBELLA, AND VARICELLA
    BRUNELL, PA
    NOVELLI, VM
    LIPTON, SV
    POLLOCK, B
    [J]. PEDIATRICS, 1988, 81 (06) : 779 - 784
  • [7] Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-Tetra™ and ProQuad™ live attenuated combined vaccines
    Tillieux, Sueli L.
    Halsey, Wendy S.
    Sathe, Ganesh M.
    Vassilev, Ventzislav
    [J]. VACCINE, 2009, 27 (16) : 2265 - 2273
  • [8] Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMT(II)V) in healthy children
    Watson, BM
    Laufer, DS
    Kuter, BJ
    Staehle, B
    White, CJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03): : 731 - 734
  • [9] Immunogenicity and safety of concomitant administration of measles-mumps-rubella vaccine and varicella vaccine by the intramuscular or subcutaneous route
    Gillet, Yves
    Habermehl, Pirmin
    Fiquet, Anne
    Thomas, Stephane
    Eymin, Cecile
    Bertrand, Isabelle
    Ledesma, Emilio
    [J]. PEDIATRICS, 2008, 121 : S164 - S164
  • [10] SAFETY AND IMMUNOGENICITY OF COMBINED MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE (MMR-V) VERSUS SEPARATE MMR AND VARICELLA VACCINES IN 144 TODDLERS
    SHINEFIELD, H
    BLACK, S
    VANOSTEN, G
    ADELMAN, T
    ENSOR, K
    STAEHLE, B
    [J]. PEDIATRIC RESEARCH, 1994, 35 (04) : A196 - A196